Cencora, Inc.
A large pharmaceutical distributor that moves branded, generic, and over-the-counter medicines from drugmakers to hospitals, retail pharmacies, and long-term care facilities around the world. The company was born from the 2001 merger of two drug wholesalers, AmeriSource Health and Bergen Brunswig, and kept the combined name AmerisourceBergen until August 2023, when it rebranded as Cencora to signal its global reach. A telling detail: its old name simply stitched the two founding companies' names together.
Sold 13.08M
Granted 616.7K · Sold 440.8K
Granted 248.5K
Granted 229.5K · Sold 143.1K
Granted 4.5K · Bought 8.5K
Granted 68.4K · Sold 21.5K
Granted 2.4K
Granted 66.8K · Sold 28.7K
Granted 2.4K
Granted 3.5K · Sold 3.0K
Granted 18.2K · Sold 12.8K
Granted 66.5K · Sold 71.4K
Granted 5.2K
Granted 28.8K · Sold 18.7K
Granted 10.5K
Granted 3.8K · Bought 550
Granted 2.2K
Granted 2.2K
Granted 3.7K
Granted 1.7K
Granted 1.1K
Granted 791
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Walgreens Boots Alliance Holdings LLC +1 co-filer10% owner · 13 transactions | — | 61.14Mas of Feb 2025 | — | — | 13.08M |
| Collis Steven HExecutive Chairman, Director · 68 transactions | +18.6% | 305.9K | 616.7K | — | 440.8K |
| Cleary James FChief Financial Officer · 39 transactions | +96.4% | 160.4K | 248.5K | — | — |
| Mauch Robert P.President & CEO, Director · 63 transactions | +57.6% | 69.2K | 229.5K | — | 143.1K |
| Durcan Dermot MarkDirector · 7 transactions | +69.6% | 31.8K | 4.5K | 8.5K | — |
| Campbell Elizabeth SExecutive Vice President · 38 transactions | +156.8% | 30.7K | 68.4K | — | 21.5K |
| Gochnauer Richard WDirector · 2 transactions | +9.3% | 28.8Kas of Mar 2024 | 2.4K | — | — |
| Battaglia SilvanaExecutive Vice President · 41 transactions | +131.3% | 27.2K | 66.8K | — | 28.7K |
| Hyle Kathleen WDirector · 2 transactions | +11.1% | 24.4Kas of Mar 2024 | 2.4K | — | — |
| Greenberg Lon RDirector · 7 transactions | -26% | 18.4K | 3.5K | — | 3.0K |
| Krikorian LazarusSVP & Chief Accounting Officer · 40 transactions | -8.4% | 17.2K | 18.2K | — | 12.8K |
| Clark GinaExecutive Vice President · 18 transactions | -50.3% | 13.3Kas of May 2024 | 66.5K | — | 71.4K |
| Nally Dennis MDirector · 16 transactions | +43.9% | 13.1K | 5.2K | — | — |
| Donato Leslie EEVP & Chief Strategy Officer · 23 transactions | +31.8% | 10.0Kas of Jul 2024 | 28.8K | — | 18.7K |
| Verma PawanEVP, Chief Data & Info Officer · 4 transactions | — | 5.1K | 10.5K | — | — |
| Tyler Lauren MDirector · 16 transactions | — | 4.4K | 3.8K | 550 | — |
| Kim Lorence H.Director · 3 transactions | +115.7% | 4.1K | 2.2K | — | — |
| Miller RedondaDirector · 3 transactions | +140.1% | 3.8K | 2.2K | — | — |
| Baumann WernerDirector · 13 transactions | — | 3.7K | 3.7K | — | — |
| Clyburn FrankDirector · 4 transactions | — | 1.7K | 1.7K | — | — |
| Ryerkerk LoriDirector · 2 transactions | — | 1.1K | 1.1K | — | — |
| Cooper EllenDirector · 4 transactions | — | 796 | 791 | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -13.81M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.